Navigation Links
Novelos Therapeutics Prices $5.5 Million Public Offering
Date:2/13/2013

ACTS
J. Patrick Genn , Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., Ph: (858) 775-7456, Email: jpgenn@novelos.com

Anne Marie Fields , Senior Vice President, LHA, Ph: (212) 838-3777, Email: afields@lhai.com, @LHA_IR_PR

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.


'/>"/>
SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novelos Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference On February 11
2. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
3. Novelos Therapeutics To Present At The Benchmark 2012 Micro Cap Discovery Investor Conference On November 29
4. Novelos Therapeutics Closes $2 Million Private Placement
5. Novelos Therapeutics Announces Enrollment of First Patient in Solid Tumor Imaging Trial with I-124-CLR1404 (LIGHT) Cancer-targeted PET Imaging Agent at UW Carbone Cancer Center
6. Novelos Therapeutics Successfully Completes Second Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
7. Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
8. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
9. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... REDWOOD CITY, Calif., March 19, 2012 Ingenuity Systems, ... life science researchers, today announced that the Weill Cornell ... iReport for use in its sequencing core facility.  Variant ... the output of whole genome and exome sequencing experiments ...
... 19, 2012  Johnson & Johnson (NYSE: JNJ) will provide ... parties on Monday, March 26th at approximately 10:30 ... College of Cardiology (ACC) Annual Scientific Sessions in ... of the EINSTEIN-PE study in treating patients with ...
Cached Medicine Technology:Weill Cornell Medical College Selects Ingenuity® Variant Analysis™ and Ingenuity® iReport™ for Sequencing Core Facility 2
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... a review published in the April issue of ... Feinstein Institute for Medical Research, says it,s time to ... approach to treating sepsis, which kills millions worldwide ... occurs when molecules released into the bloodstream to fight ... Inflammation is necessary for maintaining good health without ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3
... Current ,safe, levels of exposure set by CDC need to ... -- Children with blood lead levels well below those considered ... emotional development, British researchers report. , Currently, the maximum safe ... mcg/dl), which was set by the U.S. Centers for Disease ...
... ... professor at the University of Colorado Denver and Health Sciences Center, School of Business, ... healthcare communications company. , ... Knoxville, Tenn. (PRWEB) September 17, 2009 -- Michael Guthrie, MD, MBA, Executive in ...
... ... advisory board for PerfectServe, a healthcare communications company. , ... Knoxville, TN (PRWeb) Sept. 17, 2009 -- Alan ... company. The board provides guidance on innovative ways to leverage PerfectServe,s physician-contact network serving ...
... , , , ... with prescription drug coverage are more satisfied with their pharmacy ... those with wholly private insurance, according to the J.D. Power ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20050527/LAF028LOGO-a ) , , ...
... , PITTSBURGH, Sept. 17 ... solutions for individuals with speech, language and learning disabilities, today ... the Year award from Microsoft Corp. This award recognizes ... Microsoft software in their products. , , ...
... 17 Racial inequalities in health care access and quality ... health care costs over a four-year period according to a ... Economic Studies, a Washington-based think tank. , , ... University of Maryland found that over 30 percent of direct ...
Cached Medicine News:Health News:Even Small Amounts of Lead Harmful to Kids 2Health News:Even Small Amounts of Lead Harmful to Kids 3Health News:Dr. Michael Guthrie Named to PerfectServe Advisory Board 2Health News:Alan Weinstein Named Chairman of PerfectServe Advisory Board 2Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 2Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 3Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 4Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 5Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 6Health News:J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance 7Health News:DynaVox Mayer-Johnson Receives Microsoft Award 2Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 2Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 3Health News:Study Finds Racial Inequalities Cost U.S. Health System Over $50 Billion a Year 4
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (IFCC). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
Intended for the quantitative determination of alkaline phosphatase activity in serum or plasma. Kinetic reaction. 405 nm wavelength. 830 U/L at 30C linearity. Single vial, dry powder reagent....
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Medicine Products: